Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) – Stock analysts at HC Wainwright dropped their Q2 2026 earnings per share estimates for shares of Alnylam Pharmaceuticals in a research note issued on Monday, June 29th. HC Wainwright analyst P. Trucchio now forecasts that the biopharmaceutical company will earn $1.00 per share for the quarter, down from their previous estimate of $1.43. HC Wainwright has a “Buy” rating and a $470.00 price target on the stock. The consensus estimate for Alnylam Pharmaceuticals’ current full-year earnings is $7.47 per share. HC Wainwright also issued estimates for Alnylam Pharmaceuticals’ Q3 2026 earnings at $1.79 EPS, Q4 2026 earnings at $2.23 EPS, FY2026 earnings at $6.51 EPS, FY2027 earnings at $8.13 EPS, FY2028 earnings at $12.15 EPS, FY2029 earnings at $15.85 EPS and FY2030 earnings at $19.93 EPS.
Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) last issued its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.99 EPS for the quarter, beating the consensus estimate of $0.87 by $1.12. Alnylam Pharmaceuticals had a return on equity of 85.76% and a net margin of 11.72%.The business had revenue of $1.17 billion for the quarter, compared to the consensus estimate of $1.12 billion. During the same period last year, the business posted ($0.44) EPS. The company’s revenue was up 96.4% compared to the same quarter last year.
Get Our Latest Stock Report on Alnylam Pharmaceuticals
Alnylam Pharmaceuticals Trading Up 2.6%
Shares of NASDAQ:ALNY opened at $301.03 on Wednesday. The company has a market cap of $40.19 billion, a P/E ratio of 82.25 and a beta of 0.29. The company has a debt-to-equity ratio of 0.94, a current ratio of 3.13 and a quick ratio of 3.06. Alnylam Pharmaceuticals has a 1 year low of $273.11 and a 1 year high of $495.55. The stock’s fifty day moving average price is $295.55 and its 200-day moving average price is $329.80.
Insider Activity
In other Alnylam Pharmaceuticals news, insider Melissa Mclaughlin sold 2,286 shares of the business’s stock in a transaction dated Monday, April 6th. The stock was sold at an average price of $330.42, for a total transaction of $755,340.12. Following the completion of the sale, the insider directly owned 9,443 shares in the company, valued at $3,120,156.06. The trade was a 19.49% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director David E. I. Pyott sold 3,830 shares of the company’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $299.18, for a total transaction of $1,145,859.40. Following the sale, the director directly owned 1,582 shares of the company’s stock, valued at $473,302.76. The trade was a 70.77% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 7,740 shares of company stock worth $2,420,214 over the last three months. Insiders own 0.86% of the company’s stock.
Institutional Trading of Alnylam Pharmaceuticals
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Parallel Advisors LLC boosted its stake in shares of Alnylam Pharmaceuticals by 7.9% during the 1st quarter. Parallel Advisors LLC now owns 891 shares of the biopharmaceutical company’s stock worth $295,000 after acquiring an additional 65 shares during the last quarter. Glenmede Trust Co. NA raised its holdings in Alnylam Pharmaceuticals by 8.3% in the 1st quarter. Glenmede Trust Co. NA now owns 731 shares of the biopharmaceutical company’s stock worth $242,000 after purchasing an additional 56 shares during the period. Groupama Asset Managment raised its holdings in Alnylam Pharmaceuticals by 2.5% in the 1st quarter. Groupama Asset Managment now owns 36,767 shares of the biopharmaceutical company’s stock worth $12,165,000 after purchasing an additional 889 shares during the period. Segall Bryant & Hamill LLC purchased a new position in Alnylam Pharmaceuticals during the first quarter valued at $641,000. Finally, Janus Henderson Group PLC lifted its position in Alnylam Pharmaceuticals by 7.8% during the first quarter. Janus Henderson Group PLC now owns 147,089 shares of the biopharmaceutical company’s stock valued at $48,661,000 after purchasing an additional 10,664 shares in the last quarter. 92.97% of the stock is owned by hedge funds and other institutional investors.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.
Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.
Featured Stories
- Five stocks we like better than Alnylam Pharmaceuticals
- NextEra’s Dominion Deal Could Put It at the Center of the AI Power Race
- Amazon Could Be About to Reap the Rewards of a Software Spending Boom
- Best Buy’s Turnaround Is Gaining Traction, But Wall Street Still Needs Proof
- AI Fears Hit Nebius Stock, But Has the Growth Thesis Changed?
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
